Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    NSABP FB-7
Show Display Options
Rank Status Study
1 Recruiting Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Neratinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide
2 Completed
Has Results
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Bevacizumab
3 Completed
Has Results
Treatment With Pazopanib for Neoadjuvant Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: doxorubicin + cyclophosphamide;   Drug: paclitaxel + pazopanib;   Procedure: surgery;   Drug: pazopanib monotherapy

Indicates status has not been verified in more than two years